BRPI0607680A2 - agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio - Google Patents

agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio

Info

Publication number
BRPI0607680A2
BRPI0607680A2 BRPI0607680-7A BRPI0607680A BRPI0607680A2 BR PI0607680 A2 BRPI0607680 A2 BR PI0607680A2 BR PI0607680 A BRPI0607680 A BR PI0607680A BR PI0607680 A2 BRPI0607680 A2 BR PI0607680A2
Authority
BR
Brazil
Prior art keywords
lipid metabolism
prophylactic
sugar
therapeutic agent
metabolism abnormalities
Prior art date
Application number
BRPI0607680-7A
Other languages
English (en)
Inventor
Yuji Abe
Aki Kusunoki
Yoshiharu Hayashi
Fumihiko Akahoshi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BRPI0607680A2 publication Critical patent/BRPI0607680A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

AGENTE PROFILáTICO/TERAPêUTICO PARA ANORMALIDADES DO METABOLISMO DE AçúCAR/LIPIDIO. A presente invenção refere-se a um agente farmacêutico para o tratamento e/ou profilaxia de metabolismo anormal de glicose e lipídio no sangue associado às refeições, para o qual um método de tratamento suficiente ou um fármaco terapêutico não foi descoberto.
BRPI0607680-7A 2005-04-26 2006-04-26 agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio BRPI0607680A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005127523 2005-04-26
PCT/JP2006/308695 WO2006118127A1 (ja) 2005-04-26 2006-04-26 糖・脂質代謝異常の予防及び/又は治療薬

Publications (1)

Publication Number Publication Date
BRPI0607680A2 true BRPI0607680A2 (pt) 2009-09-22

Family

ID=37307926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607680-7A BRPI0607680A2 (pt) 2005-04-26 2006-04-26 agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio

Country Status (12)

Country Link
US (2) US20090088442A1 (pt)
EP (1) EP1882474B1 (pt)
JP (1) JP5100375B2 (pt)
KR (1) KR101333876B1 (pt)
CN (1) CN101175494B (pt)
AT (1) ATE486604T1 (pt)
BR (1) BRPI0607680A2 (pt)
CA (1) CA2605847C (pt)
DE (1) DE602006017997D1 (pt)
ES (1) ES2355156T3 (pt)
MX (1) MX2007013301A (pt)
WO (1) WO2006118127A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130076903A (ko) 2005-02-18 2013-07-08 미쓰비시 타나베 파마 코퍼레이션 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN102711761B (zh) * 2009-12-18 2015-06-03 田边三菱制药株式会社 溶出稳定化制剂
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
AU2001277754B2 (en) * 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
BR0206831A (pt) * 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
US6727261B2 (en) * 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
JP2005533771A (ja) * 2002-06-04 2005-11-10 ファイザー・プロダクツ・インク ジペプチジルペプチダーゼｉｖ阻害剤としてのフッ素化環式アミド
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
KR20130076903A (ko) * 2005-02-18 2013-07-08 미쓰비시 타나베 파마 코퍼레이션 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법

Also Published As

Publication number Publication date
MX2007013301A (es) 2008-03-07
US20090088442A1 (en) 2009-04-02
JPWO2006118127A1 (ja) 2008-12-18
WO2006118127A1 (ja) 2006-11-09
CA2605847A1 (en) 2006-11-09
EP1882474A4 (en) 2008-07-09
KR101333876B1 (ko) 2013-11-27
US20100305139A1 (en) 2010-12-02
ATE486604T1 (de) 2010-11-15
EP1882474B1 (en) 2010-11-03
EP1882474A1 (en) 2008-01-30
CN101175494B (zh) 2011-07-13
DE602006017997D1 (de) 2010-12-16
CA2605847C (en) 2014-02-04
JP5100375B2 (ja) 2012-12-19
ES2355156T3 (es) 2011-03-23
KR20080010436A (ko) 2008-01-30
CN101175494A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
EP2036574A4 (en) MEDICAL AGENT FOR THE TREATMENT OF FAT, DIABETES AND DISEASES IN CONNECTION WITH IMPROVED GLUCOSE TOLERANCE
BRPI0814957A2 (pt) Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
ITMI20041317A1 (it) Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
SE0303571D0 (sv) Medical product for moisture-sensitive medicaments
UA100111C2 (ru) Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
ATE486604T1 (de) Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel
MX2009005644A (es) Gel util para el suministro de farmacos oftalmicos.
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
TW200740452A (en) Therapeutic gastrodia extracts
WO2008148573A3 (de) Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen
BRPI0607562A2 (pt) derivados da diosmetina para o tratamento e a prevenção das patologias trombóticas
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
IL191365A0 (en) A preparation for use in the case of diseases of the metabolism of blood, including diabetes
SE0401568D0 (sv) A lock solution for medical devices, a device and a method for the application thereof
BRPI0610780A2 (pt) formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
WO2006131651A3 (fr) Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée
WO2008101724A8 (en) Use of riboflavin in the treatment of hypertension
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.